Medical Condition News

RSS

Specialized care helps child thrive despite chronic swallowing disorder

Today, 11-year-old Logan Fitzpatrick of Malverne, New York, spends his time playing baseball, practicing tae kwon do, painting, and cheering on the Mets and the Islanders.

22 May 2026

Psilocybin may provide long-lasting relief from chronic nerve pain

A single dose of psilocybin - the active compound in magic mushrooms - reduces nerve pain for up to a month and makes a widely used painkiller work more effectively, University of Reading research has found.

22 May 2026

AI-engineered p53 superproteins may reshape future cancer therapies

The Oncodarwinian Hypothesis (OdH) proposes a paradigm shift: cancer is not merely a disease but a potential macro‑immunoadaptive response – a self‑replicating algorithm that can be reprogrammed via AI‑based 3D printed p53 superproteins.

22 May 2026

Pim1 identified as promising therapeutic target for inflammatory arthritis treatment

The research team led by Professor Zhongyu Xie from Sun Yat-sen University revealed a new mechanism by which Pim1 regulated Th17 cell differentiation through mitochondrial metabolism.

22 May 2026

Gene-based therapies could transform future pancreatitis treatment

Pancreatitis is a complex inflammatory disease driven by both genetic and environmental factors. It poses substantial clinical challenges due to a lack of disease-modifying therapies.

22 May 2026

Internal mutations and microbes may drive a distinct subtype of oral cancer

A new study reveals that many oral cancers are no longer driven by traditional risk factors like smoking or Human papillomavirus infection.

22 May 2026

University of Ottawa study links heart attacks with brain damage

A new study led by a team from the University of Ottawa takes a major step forward in understanding how a heart attack can dramatically reshape brain function and trigger neurological effects, from depression and anxiety to different types of cognitive decline.

22 May 2026

Combination therapy improves response rates for chronic hepatitis B patients

The optimal management strategy for adults with immune-tolerant (IT) chronic hepatitis B infection remains undefined. This study aimed to investigate the efficacy and predictive factors of a pegylated interferon (Peg-IFN)-based treatment strategy in IT patients with chronic HBV infection.

22 May 2026

Targeting lipid enzymes triggers starvation states in aggressive tumor cells

While many American adults are trying to reduce cholesterol levels, certain cancerous tumors have a relentless appetite for the metabolite.

22 May 2026

Targeting a key protein reduces injury in steatotic liver transplantation

Steatotic donor livers are highly susceptible to post-transplant dysfunction; however, the underlying mechanisms remain incompletely understood.

22 May 2026

Brain scans find no evidence of widespread inflammation in long COVID

A new brain imaging study has found no evidence of widespread brain inflammation in patients suffering from prolonged symptoms after COVID-19 infection. Instead, the most severe long COVID symptoms were associated with increased brain activity in regions involved in mood and emotion.

22 May 2026

Semaglutide helps patients who gain weight after bariatric surgery

New UCL research supports use of the weight loss drug semaglutide for patients who do not get enough benefit from bariatric surgery.

22 May 2026

Mental disorders surpass other conditions as leading global cause of disability

Nearly 1.2 billion people worldwide are living with a mental disorder, nearly double the number recorded in 1990.

22 May 2026

Graph neural networks accelerate drug discovery for complex bone diseases

Announcing a new publication for Acta Materia Medica journal. Traditional Chinese medicine has shown therapeutic potential in treating osteoarthritis (OA) by regulating inflammation and maintaining cartilage homeostasis.

22 May 2026

How screen time, stress, and nicotine trap young adults in poor sleep

Among the younger part of the population, sleep problems, anxiety, and depression are widespread and growing issues.

22 May 2026

Could blocking inflammation help treat difficult-to-treat depression?

A small proof-of-concept RCT found that tocilizumab, an IL-6 receptor blocker, showed a non-significant but clinically suggestive pattern of improvement in difficult-to-treat depression linked to low-grade inflammation. The study found that baseline hs-CRP, rather than IL-6, may help identify patients most likely to respond, supporting larger trials of immune-targeted depression care.

22 May 2026

New genetic roadmap offers targeted treatment for rare inflammatory disorder

Not all broken genes fail in the same way: some simply stop working, while others interfere with what still works.

22 May 2026

New discovery maps how mutant colorectal tumors adapt to KRAS inhibitors

A new preclinical study led by researchers at The University of Texas MD Anderson Cancer Center and Weill Cornell Medicine has uncovered genetic and cell-state adaptive mechanisms that drive resistance to KRAS inhibitors in patients with KRAS-mutant colorectal cancer.

22 May 2026

Weight loss helps older AF patients slim down, but does not ease symptoms

An 8-month low-calorie diet plus behavioral support helped older adults with overweight or obesity and persistent atrial fibrillation lose weight safely, with no intervention-related serious adverse events. However, the LOSE-AF trial found no meaningful improvement in AF symptoms, rhythm control, AF burden, cardiac remodeling, or further AF procedure rates compared with usual care.

22 May 2026

Scientists join international collaborative to advance Parkinson’s disease research

Michael Koob, PhD, and his team from University of Minnesota Medical School have been selected to join the Collaborative Research Network (CRN), an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson's disease, through a $6 million grant awarded by Aligning Science Across Parkinson's (ASAP), in partnership with The Michael J. Fox Foundation for Parkinson's Research (MJFF).

22 May 2026